問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

List

1336Cases

2017-01-01 - 2018-12-31

Phase I

A Phase 1, double-blind, randomized, placebo-controlled, first-in-human study of orally administered JNJ-56136379 to evaluate safety, tolerability and pharmacokinetics after single ascending doses and one multiple dose regimen in healthy subjects (Part I), and after multiple dose regimens in subjects with chronic hepatitis B (Part II)

  • Condition/Disease

    Chronic hepatitis B

  • Test Drug

    JNJ-56136379

Participate Sites
5Sites

Terminated5Sites

2014-11-15 - 2016-02-28

Phase IV

Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    VELCADE®

Participate Sites
7Sites

Terminated7Sites

2010-03-01 - 2012-07-31

Phase III

A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with a 28-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg once daily in patients with type 2 diabetes, cardiovascular disease and hypertension, who exhibit inadequate glycaemic control on usual care

  • Condition/Disease

    type 2 diabetes

  • Test Drug

    dapagliflozin

Participate Sites
9Sites

Terminated9Sites

2010-08-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-01-08 - 2011-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2009-01-01 - 2010-06-30

Phase III

Evaluation Dapagliflozin inhibitor and with Metformin and controls DPP-4 (Sitagliptin) and received unilateral Metformin Metformin therapy with poor glycemic control in diabetic adult still disease international efficacy and safety of 24 weeks after a second type, multi-center, Random assignment, parallel, double-blind, curative effect control group, phase III clinical trial.

  • Condition/Disease

    Patients with type 2 diabetes who still have poor blood sugar control after taking at least 1,500 mg of Metformin daily

  • Test Drug

    Dapagliflozin/placebo; Sitagliptin/placebo

Participate Sites
8Sites

Terminated8Sites

2012-08-01 - 2013-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-06-01 - 2018-09-11

Phase III

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

  • Condition/Disease

    Type 2 diabetes mellitus

  • Test Drug

    Dapagliflozin

Participate Sites
6Sites

Terminated6Sites

2014-02-01 - 2016-01-31

Phase III

Acute Stroke Or Transient IsChemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES

  • Condition/Disease

    Patients with an acute cerebral ischemic event (minor stroke/high-risk TIA) and high risk of subsequent ischemic stroke, who could be randomised within 24 hours of symptom onset

  • Test Drug

    Ticagrelor

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

林瑞泰
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2017-01-01 - 2020-06-30

Phase III

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction

  • Condition/Disease

    Chronic Heart Failure

  • Test Drug

    Forxiga

Participate Sites
15Sites

Terminated13Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

1 77 78 79 80 81 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB